Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
CYTOKINETICS INC EVP and Chief Commercial Officer Andrew Callos exercised 14,000 non-qualified stock options for Common Stock at $23.26 per share and, on the same date, sold 14,000 shares at $79.88 per share under a Rule 10b5-1 trading plan. Following the exercise, he reports 10,000 stock options remaining. The option grant vests over four years, with 25% after one year and the balance vesting monthly over 36 months, subject to continued employment.
Cytokinetics, Incorporated insider Andrew Callos filed to sell common stock. The notice lists a planned sale of 24,000 shares of common stock on July 30, 2026, to be effected through Morgan Stanley Smith Barney LLC in connection with an exercise of stock options.
The filing also details prior Rule 10b5-1 plan sales of common stock over the past three months, including transactions on May 1, 2026, May 5, 2026, June 1, 2026, and June 30, 2026, with share counts and aggregate proceeds disclosed for each sale.
Robert I. Blum, President & CEO of Cytokinetics, exercised 7,500 stock options at $10.60 per share into common stock on July 27, 2026 and sold 7,500 shares at $80.87 per share, pursuant to a Rule 10b5-1 trading plan. Following the option exercise, 179,245 options of this type remain directly held. The filing also reports indirect holdings of 2,083 shares in each of The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust.
CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik exercised 3,500 non-qualified stock options at $7.80 per share on July 21, 2026, receiving 3,500 common shares and selling the same number at $80.59 per share. The transactions, conducted under a Rule 10b5-1 trading plan, left him holding 33,886 non-qualified stock options.
Cytokinetics, Inc. director Nancy Wysenski reported an acquisition of company stock as equity compensation. On July 15, 2026, she received 75 shares of Common Stock as a fully vested grant under the Cytokinetics Equity in lieu of Cash Retainer Program at an indicated value of $82.6200 per share. Following this grant, she directly holds 33,992 shares of Cytokinetics common stock.
WIERENGA WENDELL reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc. director Wendell Wierenga received a grant of 75 shares of common stock on July 15, 2026, at $82.62 per share under the company’s Equity in lieu of Cash Retainer Program. The shares were fully vested at grant, bringing his direct holdings to 35,563 shares.
Kaye Edward M. MD reported acquisition or exercise transactions in this Form 4 filing.
CYTOKINETICS INC director Edward M. Kaye, MD received a grant of 151 shares of common stock on July 15, 2026 under the Cytokinetics Equity in lieu of Cash Retainer Program. The shares were fully vested at grant, bringing his direct holdings to 10,434 common shares.
HENDERSON JOHN T reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc director John T. Henderson received a grant of 272 shares of common stock on 2026-07-15 at 82.62 per share under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested, bringing his direct holdings to 78,360 shares and indirect spouse-held holdings to 83 shares.
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics director Harrington Robert Arthur received a grant of 151 shares of common stock on July 15, 2026, under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested at grant, bringing his direct holdings to 21,932 shares.
Daly James M reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc director James M. Daly received a grant of 151 shares of Common Stock on 2026-07-15 under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested at grant and increase his directly held position to 3,390 shares.